'The interest in the Company’s development programs and Permetrex™ delivery technology from its recent meetings with potential collaborators at the American Academy of Dermatology meeting in Orlando has been substantial.'
http://pharmaceutical-review.com/botanix-receives-export-import-approvals-clinical-studies-dea/
Permetrex is a massive opportunity to delver early revenue for BOT and this technology alone could prove to be a company maker.
Ann: Trading Halt, page-66
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 408524 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |